vs
Archrock, Inc.（AROC）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是Archrock, Inc.的1.6倍（$622.0M vs $377.1M），Royalty Pharma plc净利率更高（34.4% vs 31.0%，领先3.5%），Archrock, Inc.同比增速更快（15.5% vs 4.8%），过去两年Archrock, Inc.的营收复合增速更高（18.5% vs 4.6%）
Archrock, Inc. 是领先的天然气压缩服务及相关设备解决方案供应商，主要服务北美油气领域，核心业务涵盖压缩系统租赁、维护、售后支持及销售，覆盖上游生产、中游运输与天然气加工板块。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
AROC vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.6倍
$377.1M
营收增速更快
AROC
高出10.7%
4.8%
净利率更高
RPRX
高出3.5%
31.0%
两年增速更快
AROC
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $377.1M | $622.0M |
| 净利润 | $116.8M | $214.2M |
| 毛利率 | 53.0% | — |
| 营业利润率 | 39.4% | 62.4% |
| 净利率 | 31.0% | 34.4% |
| 营收同比 | 15.5% | 4.8% |
| 净利润同比 | 95.4% | 2.9% |
| 每股收益（稀释后） | $0.67 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AROCRPRX
| Q4 25 | $377.1M | $622.0M | ||
| Q3 25 | $382.4M | $609.3M | ||
| Q2 25 | $383.2M | $578.7M | ||
| Q1 25 | $347.2M | $568.2M | ||
| Q4 24 | $326.4M | $593.6M | ||
| Q3 24 | $292.2M | $564.7M | ||
| Q2 24 | $270.5M | $537.3M | ||
| Q1 24 | $268.5M | $568.0M |
净利润AROCRPRX
| Q4 25 | $116.8M | $214.2M | ||
| Q3 25 | $71.2M | $288.2M | ||
| Q2 25 | $63.4M | $30.2M | ||
| Q1 25 | $70.8M | $238.3M | ||
| Q4 24 | $59.8M | $208.2M | ||
| Q3 24 | $37.5M | $544.0M | ||
| Q2 24 | $34.4M | $102.0M | ||
| Q1 24 | $40.5M | $4.8M |
毛利率AROCRPRX
| Q4 25 | 53.0% | — | ||
| Q3 25 | 48.5% | — | ||
| Q2 25 | 45.4% | — | ||
| Q1 25 | 47.4% | — | ||
| Q4 24 | 46.3% | — | ||
| Q3 24 | 44.4% | — | ||
| Q2 24 | 41.5% | — | ||
| Q1 24 | 42.1% | — |
营业利润率AROCRPRX
| Q4 25 | 39.4% | 62.4% | ||
| Q3 25 | 25.3% | 70.1% | ||
| Q2 25 | 22.5% | 36.3% | ||
| Q1 25 | 26.5% | 94.0% | ||
| Q4 24 | 24.0% | 60.9% | ||
| Q3 24 | 18.1% | — | ||
| Q2 24 | 17.6% | 50.2% | ||
| Q1 24 | 20.0% | -13.0% |
净利率AROCRPRX
| Q4 25 | 31.0% | 34.4% | ||
| Q3 25 | 18.6% | 47.3% | ||
| Q2 25 | 16.6% | 5.2% | ||
| Q1 25 | 20.4% | 41.9% | ||
| Q4 24 | 18.3% | 35.1% | ||
| Q3 24 | 12.8% | 96.3% | ||
| Q2 24 | 12.7% | 19.0% | ||
| Q1 24 | 15.1% | 0.8% |
每股收益（稀释后）AROCRPRX
| Q4 25 | $0.67 | $0.49 | ||
| Q3 25 | $0.40 | $0.67 | ||
| Q2 25 | $0.36 | $0.07 | ||
| Q1 25 | $0.40 | $0.55 | ||
| Q4 24 | $0.35 | $0.46 | ||
| Q3 24 | $0.22 | $1.21 | ||
| Q2 24 | $0.22 | $0.23 | ||
| Q1 24 | $0.26 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $1.5B | $9.7B |
| 总资产 | $4.3B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资AROCRPRX
| Q4 25 | $1.6M | $618.7M | ||
| Q3 25 | $4.1M | $938.9M | ||
| Q2 25 | $5.9M | $631.9M | ||
| Q1 25 | $4.8M | $1.1B | ||
| Q4 24 | $4.4M | $929.0M | ||
| Q3 24 | $3.7M | $950.1M | ||
| Q2 24 | $919.0K | $1.8B | ||
| Q1 24 | $1.2M | $843.0M |
总债务AROCRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益AROCRPRX
| Q4 25 | $1.5B | $9.7B | ||
| Q3 25 | $1.4B | $9.6B | ||
| Q2 25 | $1.4B | $9.5B | ||
| Q1 25 | $1.3B | $9.8B | ||
| Q4 24 | $1.3B | $10.3B | ||
| Q3 24 | $1.3B | $10.3B | ||
| Q2 24 | $894.5M | $9.8B | ||
| Q1 24 | $882.1M | $9.9B |
总资产AROCRPRX
| Q4 25 | $4.3B | $19.6B | ||
| Q3 25 | $4.4B | $19.3B | ||
| Q2 25 | $4.4B | $18.3B | ||
| Q1 25 | $4.0B | $17.6B | ||
| Q4 24 | $3.8B | $18.2B | ||
| Q3 24 | $3.8B | $18.0B | ||
| Q2 24 | $2.7B | $17.7B | ||
| Q1 24 | $2.7B | $16.1B |
负债/权益比AROCRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $214.5M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $126.7M | — |
| 自由现金流率自由现金流/营收 | 33.6% | — |
| 资本支出强度资本支出/营收 | 23.3% | — |
| 现金转化率经营现金流/净利润 | 1.84× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $119.6M | — |
8季度趋势，按日历期对齐
经营现金流AROCRPRX
| Q4 25 | $214.5M | $827.1M | ||
| Q3 25 | $164.5M | $702.6M | ||
| Q2 25 | $127.5M | $364.0M | ||
| Q1 25 | $115.6M | $596.1M | ||
| Q4 24 | $124.3M | $742.5M | ||
| Q3 24 | $96.9M | $703.6M | ||
| Q2 24 | $70.7M | $658.2M | ||
| Q1 24 | $137.7M | $664.6M |
自由现金流AROCRPRX
| Q4 25 | $126.7M | — | ||
| Q3 25 | $29.5M | — | ||
| Q2 25 | $16.0M | — | ||
| Q1 25 | $-52.5M | — | ||
| Q4 24 | $26.4M | — | ||
| Q3 24 | $26.9M | — | ||
| Q2 24 | $-20.6M | — | ||
| Q1 24 | $37.9M | — |
自由现金流率AROCRPRX
| Q4 25 | 33.6% | — | ||
| Q3 25 | 7.7% | — | ||
| Q2 25 | 4.2% | — | ||
| Q1 25 | -15.1% | — | ||
| Q4 24 | 8.1% | — | ||
| Q3 24 | 9.2% | — | ||
| Q2 24 | -7.6% | — | ||
| Q1 24 | 14.1% | — |
资本支出强度AROCRPRX
| Q4 25 | 23.3% | — | ||
| Q3 25 | 35.3% | — | ||
| Q2 25 | 29.1% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | 30.0% | — | ||
| Q3 24 | 24.0% | — | ||
| Q2 24 | 33.7% | — | ||
| Q1 24 | 37.2% | — |
现金转化率AROCRPRX
| Q4 25 | 1.84× | 3.86× | ||
| Q3 25 | 2.31× | 2.44× | ||
| Q2 25 | 2.01× | 12.06× | ||
| Q1 25 | 1.63× | 2.50× | ||
| Q4 24 | 2.08× | 3.57× | ||
| Q3 24 | 2.58× | 1.29× | ||
| Q2 24 | 2.05× | 6.45× | ||
| Q1 24 | 3.40× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AROC
| Horsepower Group Three | $112.6M | 30% |
| Horsepower Group Two | $108.5M | 29% |
| Horsepower Group One | $105.9M | 28% |
| Services | $32.9M | 9% |
| Over Counter Parts And Component Sales | $17.0M | 5% |
| Transferred At Point In Time | $1.4M | 0% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
